Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
No published randomized, controlled clinical trial has evaluated BPC-157 - including ProHealth's specific formulation - for any human health indication
For shoulder conditions driven primarily by inflammation, such as bursitis, acute tendinitis, or inflammatory arthropathy, KPV may provide targeted anti-inflammatory support without the tissue-weakening effects associated with corticosteroids
Why are BPC-157 and TB-500 being blended together
The smHLCs are functionally equivalent to published growth factor based methodologies and importantly can be produced at a greatly reduced cost and variability when compared with traditional growth factor driven approaches
Vet every supplier
